Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European Countries

BACKGROUND: Mirabegron, indicated for the treatment of overactive bladder, is contraindicated in patients with severe uncontrolled hypertension (systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥110 mm Hg). In September 2015, a Direct Healthcare Professional Communication (DHPC) le...

Descripción completa

Detalles Bibliográficos
Autores principales: Heintjes, Edith M, Bezemer, Irene D, Prieto-Alhambra, Daniel, Smits, Elisabeth, Booth, Helen P, Dedman, Daniel, He, Ying, Hoti, Fabian, Vehkala, Minna, de Vogel, Stefan, Robinson, Noah Jamie, Appenteng, Kwame, Penning-van Beest, Fernie J A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200224/
https://www.ncbi.nlm.nih.gov/pubmed/32431551
http://dx.doi.org/10.2147/CLEP.S242065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200224/
https://www.ncbi.nlm.nih.gov/pubmed/32431551
http://dx.doi.org/10.2147/CLEP.S242065

Ejemplares similares